Randomized control trial of Rabeprazole for prevention of aspirin-associated ulcers

Randomized control trial of Rabeprazole for prevention of aspirin-associated ulcers - Randomized control trial of Rabeprazole for prevention of aspirin-associated ulcers

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000853

Enrollment

100

Registered

2008-01-01

Start date

2008-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aspirin-associated ulcers

Interventions

Rabeprazole 3 months 10mg/day once per day no treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who is going to be introduced low-dose aspirin for more than four months

Exclusion criteria

Exclusion criteria: History of peptic ulcer diseases

Design outcomes

Primary

Measure	Time frame
Incidence of gastroduodenal ulcers	—

Secondary

Measure	Time frame
gastroduodenal mucosal damage assessed by modified Lanza's score hemorrhagic gastroduodenal ulcer symptoms asssessed by Gastrointestinal Symptoms Rating Scale	—

Countries

Japan

Contacts

Public ContactKeiji Ogura

University of Tokyo Clinical Research Center

keiji-tky@umin.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026